Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stefanie Jackson

Nurse Practitioner Lake City, FL Nurse Practitioner

NPI 1346204427 CMS profile 10693326

1289 Sw State Road 47, Lake City, FL 32025

Open in the dashboard

General payments

$4,235

279 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stefanie Jackson of Lake City, FL is reported in the CMS Open Payments database as having received $4,235 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $712 41
2024 General $795 50
2023 General $869 53
2022 General $857 59
2021 General $1,002 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stefanie Jackson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Stefanie Jackson were reported at $712. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Stefanie Jackson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,002 $135 $40–$426 $132
2022 $857 $152 $48–$470 $149
2023 $869 $166 $54–$529 $160
2024 $795 $173 $55–$556 $164
2025 $712 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,320 102 payments
  2. Amgen Inc. $326 20 payments
  3. Pfizer Inc. $278 14 payments
  4. Janssen Pharmaceuticals, Inc $275 23 payments
  5. Novartis Pharmaceuticals Corporation $256 18 payments
  6. Lilly USA, LLC $233 13 payments
  7. Merck Sharp & Dohme Corporation $166 10 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $138 9 payments
  9. AbbVie, Inc. $136 7 payments
  10. Exact Sciences Corporation $131 8 payments
  11. Other $975 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,235 279 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,158 89 payments
  2. Ozempic $1,141 88 payments
  3. XARELTO $275 23 payments
  4. Repatha $199 12 payments
  5. Otezla $197 12 payments
  6. VERQUVO $160 10 payments
  7. MOUNJARO $159 9 payments
  8. ENTRESTO $154 13 payments
  9. ELIQUIS $138 7 payments
  10. Kerendia $138 9 payments
  11. Other $2,625 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

3,998

Median for Nurse Practitioner: 389

Drug cost

$637,093

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 73 $113,610
Eliquis Apixaban Brand 99 $102,090
Farxiga Dapagliflozin Propanediol Brand 76 $79,645
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $46,943
Rybelsus Semaglutide Brand 14 $34,065
Jardiance Empagliflozin Brand 23 $32,846
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 28 $32,719
Trulicity Dulaglutide Brand 14 $29,108
Repatha Sureclick Evolocumab Brand 35 $28,788
Entresto Sacubitril/Valsartan Brand 15 $27,750

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $71
$71 14 —
Ozempic
  • Novo Nordisk Inc $71
$71 73 —
YUPELRI
  • Mylan Specialty L.P. $53
$53 — —
MOUNJARO
  • Lilly USA, LLC $44
$44 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record